Through the Nephrology Collaborative Group, doctors and scientists at Mayo Clinic and other medical centers collaborate to test new therapies and treatment strategies to increase the success rates of remission and enhance patient care.

Rituximab (Rituxan), a monoclonal antibody against B cells that has been used in a number of autoimmune conditions, is being studied at Mayo Clinic for the treatment of IgA nephropathy.


See a list of publications on IgA nephropathy by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.